Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors

NCT06873542 is registered in ClinicalTrials.gov with Heronova Pharmaceuticals as lead sponsor.

NCT NCT06873542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06873542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors
Lead sponsor
Heronova Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
July 8, 2022
Completion date
January 2, 2024
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors